Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group - Archive ouverte HAL Access content directly
Journal Articles Blood Year : 2015

Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Agnes Cuerci-Bres
  • Function : Author
Raffoux Emmanuel
  • Function : Author
Olivier Spertini
  • Function : Author
Eric Deconincki
  • Function : Author
Claude Cardin
  • Function : Author
Jean-François Lambert
  • Function : Author
Patrice Chevallier
Stephane De Botton
  • Function : Author
Hervé Dombret

Abstract

57th Annual Meeting of the American-Society-of-Hematology Location: Orlando, FL Date: DEC 05-08, 2015
Not file

Dates and versions

hal-01300812 , version 1 (11-04-2016)

Identifiers

  • HAL Id : hal-01300812 , version 1

Cite

Lionel Adès, Xavier Thomas, Agnes Cuerci-Bres, Raffoux Emmanuel, Olivier Spertini, et al.. Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group. Blood, 2015, 126 (23), pp.451. ⟨hal-01300812⟩
210 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More